Navigation Links
Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
Date:10/1/2007

ectable virus 24 weeks after stopping therapy, which clevudine previously demonstrated in Bukwang's South Korean registration studies.

At week 72, HBeAg- patients in Study 306 who have been treated with clevudine and have suppressed HBV DNA and normalized ALT levels will be randomized to continue active clevudine or switch to placebo. The purpose is to determine the proportion of patients who sustain a virologic response 24 weeks after stopping clevudine treatment at week 96. HBeAg+ patients in Study 305 that have been treated with either clevudine or Hepsera and undergo eAg seroconversion (loss of eAg with suppressed HBV DNA and normalized ALT) will discontinue therapy at week 72. SVR will be assessed in these HBeAg+ patients for clevudine and Hepsera 24 weeks after stopping treatment at week 96.

South Korean Registration Studies for Clevudine

Bukwang received marketing approval for clevudine from the South Korean FDA based on two 24-week, randomized (3:1), double-blind, placebo-controlled, multi-center South Korean Phase 3 registration trials in 337 patients. Study 301 enrolled 248 HBeAg+ patients who received clevudine 30 mg or a placebo once-daily, and Study 302 enrolled 89 HBeAg- patients who received clevudine 30 mg or a placebo once-daily. All patients were evaluated for an additional 24 weeks of follow-up care without clevudine treatment.

After 24 weeks of clevudine treatment, 59% of HBeAg+ patients achieved undetectable HBV DNA (<300 copies/mL) and 92% of HBeAg- patients achieved undetectable HBV DNA. These results were statistically significant compared to placebo. In addition to the potent antiviral suppression, 16% of the HBeAg- patients who received clevudine demonstrated a sustained virologic response (SVR) 24 weeks after stopping therapy, versus 0% of the patients who had received the placebo. In Study 303, a South Korean open-label, follow-on study of clevudine, Bukwang observed similar findings to those noted above for Studie
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmasset Presents Clevudine and Racivir Data at the International HIV Drug Resistance Workshop
2. Pharmasset Announces Clevudine and Hepatitis C Presentations at EASL
3. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
4. Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target
5. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
6. ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO
7. ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO
8. Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer Patients Treated with Therapy Based on Ratiometric Dosing
9. PC-DAC:Exendin-4 Phase I/II Multiple-Dose Study Preliminary Results Demonstrate Safety and Efficacy at Once-Weekly Dosing
10. Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor Data Showing Broad Anti-Tumor Activity, Dosing Flexibility
11. Active Biotechs I-3D Micro-dosing Clinical Trial Concluded
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... NEW YORK , Oct. 22, 2014 ... and dermatology therapies. PV-10, its novel investigational drug for ... the potential for systemic side effects. Its oncology focus ... liver. Provectus has completed phase 2 trials of PV-10 ... as a topical treatment for atopic dermatitis and psoriasis. ...
(Date:10/20/2014)... MOUNTAIN VIEW, Calif. , Oct. 20, 2014 /PRNewswire/ ... field of interventional pulmonology, today announced completion of enrollment ... schedule.  The RENEW Clinical Study is the FDA-approved IDE ... treatment for severe emphysema. It was anticipated ... US in February 2013, would take until the end ...
(Date:10/20/2014)... 2014 Valeritas, Inc., a leader in simple, ... Type 2 diabetes, announced today that it has received ... award was presented October 16 th at Cardinal,s ... . The Cardinal Health Supply ... of metrics specifically targeted at the importance of developing ...
Breaking Medicine Technology:Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders 2PneumRx Completes RENEW Pivotal Trial Enrollment 2PneumRx Completes RENEW Pivotal Trial Enrollment 3Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 2Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 3
... Aug. 1, 2011 Biodel Inc. (Nasdaq: BIOD ... results on August 4, 2011.  Following the release of the ... call to discuss the results and provide an update on ... fiscal year 2011 results will be distributed4:15 pm EDT: , ...
... 2011 Reportlinker.com announces that a new ... catalogue: Insulin- Global ... This package contains 63 insulin market analyses ... Czech Republic,Denmark, Estonia, Finland, France, Germany, Greece, ...
Cached Medicine Technology:Insulin- Global 2
(Date:10/22/2014)... October 22, 2014 The ... which is dedicated to distribute health information technology ... delivery worldwide announced the development of six key ... expect when receiving healthcare. These are an expansion ... care: “providing care that is respectful of and ...
(Date:10/22/2014)... Best Cheap Hosting USA is among the most distinguished ... announced that iPower ( http://www.best-cheap-hosting-usa.com/go/iPower/ ) is the best ... world. , “iPower is one of the most reliable ... kinds of useful products for new and old clients. ... service and a number of features which will appeal ...
(Date:10/22/2014)... October 22, 2014 Lintelus, Inc., an ... Vice President of Sales, will be speaking on the ... Technology Expo on October 28, at the Holiday Inn ... a booth as well as a Tech Demo at ... can create a more engaging event experience. , The ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. ... fertilization (IVF) are only about half as likely as white ... new research indicates, and the racial disparity persists even when ... percent of white patients became pregnant after IVF, compared to ... 4,000 IVF cycles over two years to tease out the ...
(Date:10/22/2014)... Measures taken by Firestone officials at the company,s ... the spread of the disease there and could prove ... Co. provides health services to about 80,000 employees, retirees, ... Between Aug. 1 and Sept. 23, there were ... people. That incidence rate of 0.09 percent was much ...
Breaking Medicine News(10 mins):Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2
... country's greenest and cleanest city was not enough, Chandigarh is all ... become the first smoke-free city in the country. ... free by July 1. ,The joint capital of Punjab ... and buildings to ensure that smoking is restricted and the general ...
... a million less AIDS patients than has been widely believed, ... were reported here. ,The survey that was ... out under international supervision shows that India probably no longer ... the New York Times said Friday. ,An official ...
... epilepsy in developing countries are being denied an effective ... according to an editorial in this weeks BMJ. ... in developing countries to ensure that effective treatment is ... people with epilepsy who live in developing countries, around ...
... (hESC), those very young cells that are a biological blank ... to the workings of a wide variety of organs and ... slow to be realized because of the ongoing ethical debate ... its a politically charged issue in the U.S. because it ...
... of tumors and the response of tumors to radiation ... in turn limits oxygen delivery to the tumor, causing ... shown to trigger tumor resistance to radiation via the ... known as HIF-1regulated cytokines. In a study appearing online ...
... community hospita,l in Detroit with 285 beds, specializing in general ... failure, diabetes and obstetrics. ,Detroit is the largest ... a prosperous region. ,But Riverview is all ... week said it was losing too much money and already ...
Cached Medicine News:Health News:Chandigarh to Become India's First Smoke-free City 2Health News:India Has a Million Less AIDS Cases Than Believed: Study 2Health News:Dartmouth Professor Makes Case for Ethically Universal Stem Cell Lines 2Health News:Hospitals in Older Cities Close Down, Blacks Worst Affected 2Health News:Hospitals in Older Cities Close Down, Blacks Worst Affected 3
... As the leader in liquid handling, ... Finnpipette Novus, a pipette that combines simplicity, ... ergonomic design. Built on the results of ... the new Finnpipette Novus gives you the ...
... The StaRRsed-III is a system ... human blood samples. This rate may ... patients therapy. The sedimentation rate is ... hence is typically used in high-volume ...
... complete range of automatic systems for performing ... mL of blood. With the introduction of ... clinical diagnostic market a truly revolutionary testing ... limitation associated with the traditional ESR techique.,By ...
... The NEW VACUETTE erythrocyte sedimentation ... can help. The new generation unites ... analysers with whole range of additional ... of the erythrocyte sedimentation rate. Cost ...
Medicine Products: